|
Active substance |
Ruxolitinib |
|
Holder |
Novartis Pharma |
|
Status |
Running |
|
Indication |
the treatment of Corticosteroid-refractory chronic graft vs. host disease after allogeneic stem cell transplantation, for pediatric patients younger than 12 years who cannot be adequately treated with commercially available alternatives |
|
Public documents |
|
|
Last update |
22/06/2023 |
Jakavi
Last updated on